Click here to Download this video

To download video: Right click on the following button and select "Save Link As"

To download mp3 (audio): Click "Download mp3" button

Download mp3

In-Depth AbbVie Stock Analysis | Poised for Massive Gains

Stock Investment Analysis

Subscribers 8.69K subscribers

9,604 views


Share with Link:
Published on Jul 19, 2020
Welcome to the most in-depth Stock Investment Analysis video. In today’s video, we take a deep dive into the biopharmaceutical company, AbbVie. This is a company I believe will generate over 30% returns annually. In my video on stocks I am buying in July, I mentioned I own and am adding to AbbVie this month and would be doing an in-depth analysis into the company. Wait no further it is here! In this video, I will explain AbbVie’s business, why the share price decreased in the past few years, why it has rebounded, and why I believe it will continue to increase as I analyze future directions. I will also give a close examination of valuation, the dividend, debt, historical and future capital gains, margins, revenue, risk, and all the important information we need to consider when deciding whether to invest. Please take a moment to like the video. Videos like this one take an enormous amount of time to create so I would truly appreciate your help in getting it out to more people who are interested. Make sure to subscribe and hit the bell so you never miss a future video.

Using Fast Graphs, Finbox, and Fidelity, I analyze AbbVie’s Company Characteristics, Historical Growth, Forecasted Growth, Dividends, Returns, Valuation, Margins, and Company Safety. Within those categories, I analyze a large number of variables including: price to earnings ratio, price to sales ratio, price to free cash flow ratio, price to book ratio, dividend, dividend yield, debt to equity ratio, fair value, target price, forward pe, the PEG ratio, EPS, EPS growth, dividend growth, return on assets (ROA), return on equity (ROE), return on investment (ROI), normal PE, forward price to sales, interest coverage, short term debt coverage, debt paydown yield, current ratio, quick ratio, free cash flow yield, and beta. I compare AbbVie stock to its own history and as well as to the industry. I also analyze AbbVie’s business, diversification across drugs, risks, and future prospects. For those who are interested in dividend growth stocks, growth stocks, and dividend growth investing, this is a great dividend aristocrat to invest in.

I believe AbbVie has a strong history of growth and a powerful revenue generator in Humira which they will continue to earn revenue from even after its patent expiration. They will also receive royalties from Humira competitors even after Humira loses the patent protection. They have new blockbuster drugs currently building with Imbruvica, Skyrizi, and Rinvoq growing rapidly.

The synergies and diversification with Allergan are very promising, the company has a great record of growing the dividend and buying back shares, the company knows how to market its drugs. AbbVie is one of my largest positions and I will continue to add. What are your thoughts? Are you buying AbbVie? Why or why not? Leave your thoughts in the comments below. I look forward to hearing from you. Make sure you subscribe and hit the bell, so you never miss a future video. As always, good luck with your investing.

Connect on Social:
Facebook: https://www.facebook.com/groups/stock.investment.analysis/
Twitter: https://twitter.com/St0ckInvestment
Instagram: http://instagram.com/stockinvestmentanalysis

Used in this video:
www.fastgraphs.com
www.fidelity.com
www.finbox.com

DISCLOSURE: I am long ABBV.

DISCLAIMER: All information and data on this YouTube Channel is solely for entertainment purposes. The information herein is based solely on my personal opinion and experience. All investments hold inherent risk, and the information provided on this YouTube Channel should not be interpreted as guidance, recommendations, offers, advice, or suggestions. Any ideas and strategies discussed on this channel should not be implemented without first considering your financial and personal circumstances or without consulting a financial professional.
Up next
Autoplay